ACR-368 interim data from registrational-intent arms presented at ESGO for endometrial cancer serous subtype

Acrivon Therapeutics, Inc.

Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.
Data focused on endometrial cancer, particularly the serous sub-type.
KOL panel discussed potential of ACR-368 to address unmet need in this patient population.
Company-sponsored webcast with on-site and virtual participation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.